Spots Global Cancer Trial Database for idh1
Every month we try and update this database with for idh1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Non Invasive IDentification of Gliomas With IDH1 Mutation | NCT01703962 | Non Invasive Di... | 18 Years - 65 Years | Institut National de la Santé Et de la Recherche Médicale, France | ||
| Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | NCT02073994 | Cholangiocarcin... Chondrosarcoma Glioma Other Advanced ... | AG-120 | 18 Years - | Servier | |
| Non Invasive IDentification of Gliomas With IDH1 Mutation | NCT01703962 | Non Invasive Di... | 18 Years - 65 Years | Institut National de la Santé Et de la Recherche Médicale, France | ||
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy | NCT03499912 | Acute Myeloid L... | 20 Years - 100 Years | National Taiwan University Hospital | ||
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | NCT04521686 | Cholangiocarcin... Chondrosarcoma Glioma Any Solid Tumor | LY3410738 Gemcitabine Cisplatin Durvalumab | 18 Years - | Eli Lilly and Company | |
| Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | NCT02492737 | Acute Myeloid L... Myelodysplastic... Hematologic Mal... | AG881 | 18 Years - | Agios Pharmaceuticals, Inc. | |
| A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma | NCT04458272 | WHO Grade II Gl... | DS-1001b | 20 Years - | Daiichi Sankyo | |
| Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors | NCT02746081 | Solid Tumors | BAY1436032 | 18 Years - | Bayer | |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | NCT04521686 | Cholangiocarcin... Chondrosarcoma Glioma Any Solid Tumor | LY3410738 Gemcitabine Cisplatin Durvalumab | 18 Years - | Eli Lilly and Company | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | NCT02381886 | Advanced Malign... | IDH305 | 18 Years - | Novartis | |
| Study of AG-120 and AG-881 in Subjects With Low Grade Glioma | NCT03343197 | Glioma | AG-120 AG881 | 18 Years - | Servier | |
| Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | NCT02492737 | Acute Myeloid L... Myelodysplastic... Hematologic Mal... | AG881 | 18 Years - | Agios Pharmaceuticals, Inc. | |
| Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | NCT02481154 | Glioma | AG881 | 18 Years - | Servier | |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | NCT02074839 | Relapsed or Ref... Untreated AML Other IDH1-muta... Myelodysplastic... | AG-120 | 18 Years - | Servier | |
| Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors | NCT02746081 | Solid Tumors | BAY1436032 | 18 Years - | Bayer | |
| Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors | NCT02746081 | Solid Tumors | BAY1436032 | 18 Years - | Bayer | |
| A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma | NCT04458272 | WHO Grade II Gl... | DS-1001b | 20 Years - | Daiichi Sankyo | |
| Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) | NCT02989857 | Advanced Cholan... Metastatic Chol... | AG-120 Placebo | 18 Years - | Servier | |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | NCT04477291 | Acute Myeloid L... Myelodysplastic... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | NCT02381886 | Advanced Malign... | IDH305 | 18 Years - | Novartis | |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | NCT06127407 | Locally Advance... | Ivosidenib 500m... Placebo | 18 Years - | Servier | |
| Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | NCT02977689 | Glioma | IDH305 | 18 Years - | NYU Langone Health | |
| Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | NCT02977689 | Glioma | IDH305 | 18 Years - | NYU Langone Health |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
